Meeting
2023 ASCO Annual Meeting
Longitudinal MRI-based fusion novel model to predict pathological complete response in breast cancer treated with neoadjuvant chemotherapy: A multicenter, retrospective study.
Authors
Kun Wang
Department of Breast Cancer, Cancer Center, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China
Kun Wang , Yuhong Huang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Neoadjuvant Therapy
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 599)
DOI
10.1200/JCO.2023.41.16_suppl.599
Abstract #
599
Poster Bd #
429
Abstract Disclosures
Similar Posters
Poster
2012 ASCO Annual Meeting
Magnetic resonance imaging (MRI) evaluation of pathologic complete response (pCR) in different breast cancer subtypes after neoadjuvant chemotherapy (NAC).
First Author: Lucia Gonzalez-Cortijo
Poster
2023 ASCO Annual Meeting
Selective avoidance of sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with HER-2 positive/triple negative breast cancer: Prospective, multi-center, single-arm study (ASLAN).
First Author: Jai Min Ryu
Poster
2023 ASCO Annual Meeting
Metformin with neoadjuvant chemotherapy in localized triple negative and HER2neu-positive breast cancer: A prospective phase 2 open label randomised controlled trial (McBETH).
First Author: Mouna Bidaraguppe B M
Poster
2022 ASCO Quality Care Symposium
Factors predicting pathological complete response in patients with localized breast cancer receiving neoadjuvant chemotherapy.
First Author: Arya Mariam Roy